Q-omics provides the consensus-scored ZNF275 profile across patient tissues and cancer cell-line models. ZNF275 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ZNF275 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, ZNF275 RNA expression shows 19,919 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, HNSC, and UVM as cancer lineages where ZNF275 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF275 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF275 survival associations across molecular data types. ZNF275 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF275 RNA expression–survival associations across cancer types. High ZNF275 expression shows unfavorable associations in KIRP, UVM and COAD, but favorable associations in SKCM, LGG and PAAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for ZNF275 RNA expression.
This table summarizes ZNF275 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZNF275. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF275 shows lower tumor expression in THCA and higher tumor expression in HNSC, COAD, READ, LUAD and STAD. The HNSC box plot shows higher ZNF275 RNA expression in tumor versus normal tissue (log2 FC = +1.365, t-test p < 0.001).
This table shows molecular features associated with ZNF275 in patient tissues and cancer cell lines. In patient samples, ZNF275 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF275 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and KIDNEY.
